VH-937 demonstrates robust antiviral activity against HIV-1 strains resistant to prior maturation inhibitors

March 21, 2024

Researchers from Viiv Healthcare Ltd. presented preclinical data for the next-generation maturation inhibitor (MI) VH-3739937 (VH-937, zegruvirimat), currently in clinical testing for the treatment of HIV.

BioWorld Science Conferences Conference on Retroviruses and Opportunistic Infections Infection HIV/AIDS

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 19, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...